Leerink Partners Initiates Coverage On Obsidian Therapeutics with Outperform Rating, Announces Price Target of $32
OB
Obsidian Therapeutics, Inc OBX
$12.86
▼ -4.10%
($-0.55)
🎢 High Beta
Open
$13.54
Prev Close
$13.41
Day Range
$12.16 – $13.70
52W Range
$13.20 – $49.97
Market Cap
$794.40M
Beta
6.14
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| Website | obsidiantx.com ↗ |
| Phone | 13026587581 |
| Listed | 2026-08-04 |
| Shares Out. | 61,772,876 |
About Obsidian Therapeutics, Inc
Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.
Obsidian Therapeutics, Inc is a publicly traded company under the ticker symbol OBX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.